WuXi AppTec Acquires US-Based Pharmapace

Pharmapace will become a wholly-owned subsidiary of WuXi Clinical and will continue to focus on growing its core biometrics competences.

Zuellig Pharma Acquires Singapore Healthcare Startup Klinify

Zuellig Pharma has acquired Singapore-based healthtech startup Klinify for an undisclosed amount.

Ambrx And BeiGene To Jointly Develop Next-Gen Biologics

Under the terms of the collaboration with BeiGene, Ambrx will receive US$10 million to fund the initial discovery and research activities for novel biologic drug candidates.

ASLAN Partners BioGenetics To Commercialize Varlitinib

ASLAN Pharmaceuticals will focus on clinical development of varlitinib while BioGenetics will obtain the necessary regulatory approvals for the use of the drug in South Korea.

WuXi STA And BioLingus Partner On Drug Delivery

The collaboration leverages BioLingus' platform for stabilizing and delivering drugs via tissues under the tongue.

Takeda Completes Acquisition Of Shire

The acquisition of Shire allows Takeda to expand its R&D efforts in four therapeutic areas: oncology, gastroenterology, neuroscience and rare diseases.

Zai Lab Launches Field Therapy For GBM In Hong Kong

The treatment method, which relies on electric fields to destroy tumors, can now be used to treat patients in Hong Kong diagnosed with an aggressive type of brain cancer.

China Approves Tyvyt For Hodgkin’s Lymphoma

Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody, was co-discovered by Innovent and Adimab and jointly developed by Innovent and Eli Lilly in China.

AUM Biosciences Licenses Cancer Drug From A*STAR

The drug, ETC-206, was shown to be well tolerated in human trials and specifically targets cancer cells while leaving normal cells unharmed.